Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.…
Alector (ALEC) Stock Sees Fair Value Lift As Analysts Split On Genentech Deal
Alector (NASDAQ: ALEC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 103 employees.
The shares were at 2.335 USD on 20 November 2026, up 79.6% over 52 weeks. Its 52-week range is 1.090 USD to 2.840 USD: the price is 17.8% below the high and 114.2% above the low.
At a market capitalisation of 347.63M USD, it trades at 6.3 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 81% for ALEC.
Alector reports return on equity of -466.3% and an operating margin of 21.8%.
It holds more cash than debt, a net cash position of 117.70M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 4.417 USD is 89.2% above the current price. The next earnings report is expected on 25 February 2027.